News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

IntelGenx Corp. And RedHill Biopharma Ltd. (RDHL) Provide An Update On FDA's Ongoing Review Of The NDA For Migraine Versafilm™ Product



4/24/2014 8:58:22 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAINT LAURENT, Quebec, April 24, 2014 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX: IGXT) ("IntelGenx"), a Canadian drug delivery company focusing on oral drug delivery, together with RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs, today reported that the U.S. Food and Drug Administration ("FDA") acknowledged receipt of their response to the Complete Response Letter ("CRL") for the VersaFilmâ„¢ Oral Film Product New Drug Application ("NDA") and has requested further clarifications. The VersaFilmâ„¢ Oral Film Product is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   
Migraine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES